About Merus
Merus is a company based in Utrecht (Netherlands) founded in 2003 was acquired by Genmab in December 2025. It operates as a HealthTech. Merus has raised $156.19 million across 11 funding rounds from investors including Pfizer, Genmab and RA Capital. The company has 260 employees as of December 31, 2024. Merus offers products and services including Multiclonics Platform and Clinical Trials. Merus operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Utrecht, Netherlands
- Employees 260 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Merus N.V.
-
Annual Revenue
$36.13 M-17.78as on Dec 31, 2024
-
Net Profit
$-215.33 M-38.97as on Dec 31, 2024
-
EBITDA
$-269.6 M-75.05as on Dec 31, 2024
-
Total Equity Funding
$156.19 M (USD)
in 11 rounds
-
Latest Funding Round
$15 M (USD), Post-IPO
Dec 20, 2018
-
Investors
Pfizer
& 14 more
-
Employee Count
260
as on Dec 31, 2024
-
Acquired by
Genmab
(Dec 12, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Merus
Merus is a publicly listed company on the NASDAQ with ticker symbol MRUS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Merus
Merus offers a comprehensive portfolio of products and services, including Multiclonics Platform and Clinical Trials. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative platform used for developing cancer treatment therapies.
Trials conducted to test new cancer treatment solutions.
Unlock access to complete
Unlock access to complete
Leadership Team
39 people
Software Development Team
17 people
Senior Team
15 people
Finance and Accounting
11 people
Operations Team
10 people
Legal and Compliance
5 people
Product Management Team
4 people
Scientific Team
4 people
Unlock access to complete
Funding Insights of Merus
Merus has successfully raised a total of $156.19M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Post-IPO — $15.0M
- First Round First Round
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2018 | Amount | Post-IPO - Merus | Valuation |
investors |
|
| Feb, 2018 | Amount | Post-IPO - Merus | Valuation |
investors |
|
| Jan, 2017 | Amount | Post-IPO - Merus | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Merus
Merus has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Genmab and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Founded Year | Domain | Location | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
Investments are made in innovative life science companies globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Merus
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Merus
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Merus Comparisons
Competitors of Merus
Merus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Merus
Frequently Asked Questions about Merus
When was Merus founded?
Merus was founded in 2003 and raised its 1st funding round 3 years after it was founded.
Where is Merus located?
Merus is headquartered in Utrecht, Netherlands.
Is Merus a funded company?
Merus is a funded company, having raised a total of $156.19M across 11 funding rounds to date. The company's 1st funding round was a Post-IPO of $80M, raised on Jan 17, 2006.
How many employees does Merus have?
As of Dec 31, 2024, the latest employee count at Merus is 260.
What is the annual revenue of Merus?
Annual revenue of Merus is $36.13M as on Dec 31, 2024.
What does Merus do?
Merus is engaged in the discovery and development of new cancer treatments. The company operates in the biotechnology sector, leveraging its proprietary Multiclonics Platform to create therapeutic solutions. Clinical trials are conducted to test and validate these treatments, aiming to address unmet needs in cancer care. Based in Utrecht, Netherlands, with an additional office in Cambridge, USA, Merus is committed to advancing healthcare through innovative research and development.
Who are the top competitors of Merus?
Merus's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Merus offer?
Merus offers Multiclonics Platform and Clinical Trials.
Is Merus publicly traded?
Yes, Merus is publicly traded on NASDAQ under the ticker symbol MRUS.
Who are Merus's investors?
Merus has 15 investors. Key investors include Pfizer, Genmab, RA Capital, Life Sciences Partners, and Tekla Capital Management.
What is Merus's ticker symbol?
The ticker symbol of Merus is MRUS on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.